A three panel study, to determine if MK8266 given as a single dose is sufficiently safe and well tolerated. Panel A and B will consist of healthy young males and Panel C will consist of subjects with mild to moderate hypertension.

safety and tolerability of single doses of MK8266 measured by number of clinical and laboratory adverse experiences [ Time Frame: 14 days after administration of last dose of study drug ] [ Designated as safety issue: Yes ]

For Panel A and B Subject is a healthy male between 18 to 45 years of age. For Panel C subject is a male with essential hypertension between 18 to 55 years of age

Subject is a non-smoker

Exclusion Criteria:

Subject has a history of stroke, chronic seizure or major neurological disorder

Subject has a disability that can interfere with rising from a sitting position to the standing position

Subject has a personal of family history of bleeding or clotting disorders

Subject has a history of cancer

Subject is unable to refrain from or anticipates the use of any prescription or nonprescription drug during the study

Subject consumes excessive amounts of caffeine or alcohol

Subject has had major surgery, donated blood or participated in another investigational study in the past 4 weeks

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01025791